Lushi Avner bought SLXN
February 20, 2026 · Form 4 insider transaction
Lushi Avner bought 9,091 shares of Silexion Therapeutics Corp at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 3 days after the transaction.
Footnotes
The transaction reported in this row consists of the grant to Guangzhou Sino-Israel Biotech Fund ("GIBF") by the Issuer of fully vested restricted share units (RSUs), which were immediately settled for underlying ordinary shares, par value $0.0135 per share ("ordinary shares|), in respect of director services provided by the Reporting Person to the Issuer. The grant was approved by the Issuer's board of directors.; The Reporting Person possesses shared voting and investment authority with respect to the securities reported in this row as a result of his serving as a Managing Partner and CEO of GIBF. The equity interests of GIBF are held by various individuals and entities. The Reporting Person disclaims beneficial ownership of the securities reported in this row except to the extent of his indirect pecuniary interest therein.